Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab +/- Azacitidine in Hematological Malignancies
NCT03248479Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2017
- Primary completion
- Sep 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of magrolimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-emergent Adverse Events up to 4 years, Complete Remission Rate For Participants With AML up to 5 years and 2 more. Started Sep 2017; status: terminated.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03248479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248479.